More Articles

Access and Evidence

Artificial Intelligence: Friend Or Foe?

Adam Chapman, (Nov 23, 2017)

AI is fast becoming a reality. What does this mean for medical affairs?
Access and Evidence

Instant Feedback

Adam Chapman, (Nov 22, 2017)

Insights derived from “real-life” data are being billed as the next phase of pharma. But are payers convinced?
Access and Evidence

Can Blockchain Solve Pharma’s Trust Problem?

Tom Disley, (Nov 20, 2017)

The Economist calls it “the trust machine” but can blockchain rejuvenate pharma’s savaged public image?
Patients and Medical

Medical Meets Machine

Danielle Barron, (Nov 15, 2017)

Pharma needs to be at the intersection between technological innovation and medical insight
Access and Evidence

The Price Of Access

Lucy Fulford, (Nov 13, 2017)

With tight purse strings right across the world, innovative pricing schemes are a crucial step in delivering affordable healthcare
Access and Evidence

A Bright Future

Lucy Fulford, (Nov 9, 2017)

Innovation is disrupting the entire healthcare continuum, creating opportunities for Medical Affairs in new and exciting places, says BMS’ Lav Parvathenani.
Access and Evidence

Surfing The Data Tsunami

Danielle Barron, (Nov 8, 2017)

How pharma is working together with government, regulators, tech companies and their industry peers to establish a strong foundation for health data across Europe
Patients and Medical

Digging For Gold

Lucy Fulford, (Nov 1, 2017)

As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?
Access and Evidence

Under Pressure

Hugh Gosling, (Oct 31, 2017)

Pharma must lay its cards on the table and build a more transparent relationship with payers
Access and Evidence


Hugh Gosling, (Oct 26, 2017)

An expert powerhouse involved in key strategic decisions right across the lifecycle, Market Access has come a long way in a short time